The U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda) in combination with pemetrexed and platinum chemotherapy as first-line treatment of unresectable advanced or metastatic malignant pleural mesothelioma.
Positive results from the phase III NIAGARA trial showed perioperative treatment with the PD-L1 blocker durvalumab in combination with neoadjuvant chemotherapy demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of event-free survival and the key secondary endpoint of overall survival vs neoadjuvant chemotherapy alone for patients with muscle-invasive bladder cancer. Patients were treated with durvalumab in combination with neoadjuvant chemotherapy before radical cystectomy followed by durvalumab as adjuvant monotherapy.
An updated overall survival analysis of the phase III HIMALAYA study, now at 5 years, has confirmed the robust benefit for the STRIDE regimen of durvalumab plus tremelimumab in unresectable hepatocellular carcinoma.At the European Society for Medical Oncology (ESMO) Congress 2024 (Abstract 947MO), investigators reported a doubling of 5-year survival, which was 19.6% with STRIDE vs 9.4% with sorafenib alone—a 24% reduction in the risk of death. This benefit was accentuated in patients achieving disease control, and no additional safety concerns were observed with extended follow-up.
Updated data from the global, multicenter, single-arm phase II TRUST-II trial, which were reported by Liu et al during the International Association for the Study of Lung Cancer (IASLC) 2024 World Conference on Lung Cancer (WCLC; Abstract MA06.03), continued to demonstrate robust overall and intracranial responses with the next-generation ROS1 tyrosine kinase inhibitor taletrectinib in patients with locally advanced or metastatic ROS1-positive non–small cell lung cancer (NSCLC), regardless of their prior tyrosine kinase inhibitor exposure status and geographic region.
Studies reported at the European Society for Medical Oncology (ESMO) Congress 2024 reveal new groups of women with early-stage cervical and endometrial cancers who gain clinically meaningful benefit from adding immunotherapy to current standard treatments, and a first-in-human study found “promising” antitumor activity with a novel antibody-drug conjugate targeting the protein claudin 6 in heavily pretreated patients with ovarian and endometrial cancers.
In a phase III study conducted in China, the bispecific antibody ivonescimab demonstrated a statistically significant and clinically meaningful improvement in progression-free survival compared with the PD-1 inhibitor pembrolizumab as a first-line treatment of PD-L1–positive advanced non–small cell ...
As reported by Joensuu et al in JAMA Network Open, long-term follow-up of the European SOLD trial indicates the addition of adjuvant trastuzumab to chemotherapy for 9 weeks vs 1 year continued to show poorer disease-free survival in patients with HER2-positive breast cancer, with no difference in...
In certain regions of the world, cancer claims more lives than HIV, tuberculosis, and malaria combined, yet surgery has been relegated to the sidelines of global health initiatives. This critical need to address global inequities in access to safe, timely, and affordable cancer surgery led to the...
The antibody-drug conjugate ifinatamab deruxtecan (I-DXd) showed clinically meaningful responses in pretreated patients with extensive-stage small cell lung cancer (SCLC) in an interim analysis of the phase II IDeate-Lung01 study. The findings were presented at the International Association for the ...
Cabozantinib may be effective at improving progression-free survival in patients with previously treated neuroendocrine tumors, according to recent findings presented by Chan et al at the European Society for Medical Oncology (ESMO) Congress 2024 (Abstract 1141O) and simultaneously published in The ...
In patients with early-stage triple-negative breast cancer, the addition of atezolizumab to standard adjuvant chemotherapy provided no benefit over chemotherapy alone in the final analysis of the phase III ALEXANDRA/IMpassion030 trial. The results were presented at the 2024 European Breast Cancer...
Researchers have found that about 50% of patients with metastatic melanoma treated with a combination of nivolumab and ipilimumab experienced cancer-free survival of 10 years or longer, according to a recent study published by Wolchok et al in The New England Journal of Medicine. Background In...